NASDAQ$BBNX
Beta Bionics Inc · Q1 2025 earnings
Q1 2025 earnings ·
Briefing
Beta Bionics reported Q1 2025, revenue of $12M, a net loss of $25M, diluted EPS of ($0.55).
For Q1 2025, Beta Bionics reported revenue of $12M, a net loss of $25M, diluted EPS was ($0.55). The filing highlights segment performance, liquidity, and management commentary on the period.
- Revenue $12M.
- Net loss $25M.
- Diluted EPS ($0.55).
Headline financials
Revenue & EPS history
Beta Bionics Inc · Revenue · Quarterly
$17.6M
Forward guidance
Management discusses operating priorities, capital allocation, and sector risks in the quarterly filing.
Tailwinds
- Headline results and segment trends anchor the quarter.
- Liquidity and balance-sheet capacity support operations.
- Strategic initiatives outlined in MD&A.
Headwinds
- Macro, rates, or input costs may pressure margins.
- One-time items affect year-over-year comparability.
- Execution risk on growth or restructuring plans.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 5 quarterly earnings reports · overlaid with Q1 2025
-0.7%
Avg return
Earnings day
+7.3%
Avg return
5 days after
+18.0%
Avg return
30 days after
40%
2 / 5 earnings
Positive
+4.8%
Q2 2025
Best reaction
-5.0%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.0% | -13.5% | -17.7% | |
| Q4 2025 | -2.6% | -1.5% | -23.4% | |
| Q3 2025 | +2.2% | +14.6% | +29.9% | |
| Q2 2025 | +4.8% | +17.2% | +33.7% | |
| Q1 2025 | -2.8% | +19.4% | +67.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro